Sabril and Increased upper airway secretion - a phase IV clinical study of FDA data

Summary:

Increased upper airway secretion is reported as a side effect among people who take Sabril (vigabatrin), especially for people who are female, 2-9 old, have been taking the drug for 1 - 6 months also take Topamax, and have Infantile spasms.

The phase IV clinical study analyzes which people have Increased upper airway secretion when taking Sabril. It is created by eHealthMe based on reports of 12,433 people who have side effects when taking Sabril from the FDA, and is updated regularly.

What is Sabril?

Sabril has active ingredients of vigabatrin. eHealthMe is studying from 12,445 Sabril users. Check the latest studies of Sabril.

What is Increased upper airway secretion?

Increased upper airway secretion is found to be associated with 619 drugs and 627 conditions by eHealthMe. Check the latest studies of Increased upper airway secretion.

On Jul, 17, 2026

12,433 people reported to have side effects when taking Sabril.
Among them, 11 people (0.09%) have Increased upper airway secretion.

Could Sabril cause Increased upper airway secretion?

Among these 11 people:

How long have people been on Sabril when they have Increased upper airway secretion? *

What is the gender of people who have Increased upper airway secretion when taking Sabril? *

female: 54.55 %
male: 45.45 %

What is the age of people who have Increased upper airway secretion when taking Sabril? *

What are other drugs people take besides Sabril? *

What are other side effects people have besides Increased upper airway secretion? *

Seizures (abnormal excessive or synchronous neuronal activity in the brain): 3 people, 27.27%
Fever: 2 people, 18.18%
Urinary Tract Infection: 2 people, 18.18%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 2 people, 18.18%
Rhinovirus Infection: 2 people, 18.18%
Respiratory Disorder (respiratory disease): 2 people, 18.18%
Enterococcal Infection: 1 person, 9.09%
Fall: 1 person, 9.09%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 1 person, 9.09%
Enterovirus Infection: 1 person, 9.09%

What are the existing conditions these people have? *

Infantile Spasms: 6 people, 54.55%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 3 people, 27.27%
Temporal Lobe Epilepsy (a term that refers to a condition where seizures are generated in the portion of the brain called the temporal lobe): 1 person, 9.09%
Mitochondrial Myopathy (the muscle fibres do not function due to damage of mitochondria): 1 person, 9.09%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 9.09%
Asthma: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Sabril and have Increased upper airway secretion?

- Check whether Increased upper airway secretion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sabril:

Sabril (12,445 reports)

Browse all side effects of Sabril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Increased upper airway secretion:

Increased upper airway secretion (619 drugs)

Browse all the conditions that are associated with Increased upper airway secretion:

Increased upper airway secretion (627 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on vigabatrin (the active ingredients of Sabril) and Sabril (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.